Interaction Checker

Dutastéride : interactions médicamenteuses

Dutastéride (Avodart), inhibiteur de la 5-alpha-réductase, présente 67 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 2 de niveau majeur, 20 de niveau modéré, 35 de niveau mineur et 10 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

Interactions d'après la notice

Interactions majeures (2)

  • Dutastéride et tamsulosineinhibiteur de la 5-alpha-réductaseMajeure

    Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to dutasteride or other 5 alpha-reductase inhibitors [see Adverse Reactions (6.2) ]. (notice Dutastéride, Contre-indications)

  • Finastérideinhibiteur de la 5-alpha-réductaseMajeure

    Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to dutasteride or other 5 alpha-reductase inhibitors [see Adverse Reactions (6.2) ]. (notice Dutastéride, Contre-indications)

Interactions modérées (20)

  • Amlodipineinhibiteur calcique dihydropyridiniqueModérée

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (notice Dutastéride, Interactions médicamenteuses)

  • Amlodipine et atorvastatineinhibiteur calcique dihydropyridiniqueModérée

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (notice Dutastéride, Interactions médicamenteuses)

  • Amlodipine et bénazéprilinhibiteur calcique dihydropyridiniqueModérée

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (notice Dutastéride, Interactions médicamenteuses)

  • Amlodipine et olmésartaninhibiteur calcique dihydropyridiniqueModérée

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (notice Dutastéride, Interactions médicamenteuses)

  • Amlodipine et valsartaninhibiteur calcique dihydropyridiniqueModérée

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (notice Dutastéride, Interactions médicamenteuses)

  • Digoxineglycoside digitaliqueModérée

    Digoxin Dutasteride capsules do not alter the steady-state pharmacokinetics of digoxin when administered concomitantly at a dose of 0.5 mg/day for 3 weeks [see Clinical Pharmacology (12.3) ]. (notice Dutastéride, Interactions médicamenteuses)

  • Diltiazeminhibiteur calciqueModérée

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (notice Dutastéride, Interactions médicamenteuses)

  • Félodipineinhibiteur calcique dihydropyridiniqueModérée

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (notice Dutastéride, Interactions médicamenteuses)

  • Isradipineinhibiteur calcique dihydropyridiniqueModérée

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (notice Dutastéride, Interactions médicamenteuses)

  • Itraconazoleantifongique azoléModérée

    Dutasteride Oxybutynin Sildenafil (for erectile dysfunction) Tadalafil (for erectile dysfunction and benign prostatic hyperplasia) Tolterodine Monitor for adverse reactions. (notice Itraconazole, Interactions médicamenteuses)

  • Lopinavir et ritonavirantirétroviralModérée

    Use with caution in patients taking potent, chronic cytochrome P450 (CYP)3A4 enzyme inhibitors (e.g., ritonavir). (notice Dutastéride, Interactions médicamenteuses)

  • Nicardipineinhibiteur calcique dihydropyridiniqueModérée

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (notice Dutastéride, Interactions médicamenteuses)

  • Nifédipineinhibiteur calcique dihydropyridiniqueModérée

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (notice Dutastéride, Interactions médicamenteuses)

  • Nimodipineinhibiteur calcique dihydropyridiniqueModérée

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (notice Dutastéride, Interactions médicamenteuses)

  • Nirmatrelvir et ritonavirantiviralModérée

    Use with caution in patients taking potent, chronic cytochrome P450 (CYP)3A4 enzyme inhibitors (e.g., ritonavir). (notice Dutastéride, Interactions médicamenteuses)

  • Nisoldipineinhibiteur calcique dihydropyridiniqueModérée

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (notice Dutastéride, Interactions médicamenteuses)

  • Olmésartan, amlodipine et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (notice Dutastéride, Interactions médicamenteuses)

  • RitonavirantirétroviralModérée

    Use with caution in patients taking potent, chronic cytochrome P450 (CYP)3A4 enzyme inhibitors (e.g., ritonavir). (notice Dutastéride, Interactions médicamenteuses)

  • Telmisartan et amlodipineantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (notice Dutastéride, Interactions médicamenteuses)

  • Vérapamilinhibiteur calciqueModérée

    Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (notice Dutastéride, Interactions médicamenteuses)

Mentions mineures (35)

  • AmiodaroneantiarythmiqueMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • Aprépitantinhibiteur du CYP3A4Mineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • AtazanavirantirétroviralMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • CénobamateanticonvulsivantMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • CiclosporineimmunosuppresseurMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • Cimétidineantihistaminique H2Mineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • Clarithromycineantibiotique macrolideMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • DarunavirantirétroviralMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • Darunavir et cobicistatantirétroviralMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • DronédaroneantiarythmiqueMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • ÉfavirenzantirétroviralMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • Éfavirenz, lamivudine et ténofovirantirétroviralMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • Elvitégravir, cobicistat, emtricitabine et ténofovirantirétroviralMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • Érythromycineantibiotique macrolideMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • ÉvérolimusimmunosuppresseurMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • Fluconazoleantifongique azoléMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • FosamprénavirantirétroviralMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • Fosaprépitantinhibiteur du CYP3A4Mineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • Imatinibinhibiteur du CYP3A4Mineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • IsoniazideantibiotiqueMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • Ivacaftorinhibiteur du CYP3A4Mineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • Kétoconazoleantifongique azoléMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • LénacapavirantirétroviralMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • Mifépristoneinhibiteur du CYP3A4Mineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • Mirabégronagoniste bêta-adrénergiqueMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • NéfazodoneantidépresseurMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • Palbociclibinhibiteur du CYP3A4Mineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • PérampanelanticonvulsivantMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • Posaconazoleantifongique azoléMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • Ranolazinemédicament allongeant l'intervalle QTMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • Suvorexantsédatif-hypnotiqueMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • TamsulosinealphabloquantMineure

    Coadministration of dutasteride and tamsulosin resulted in similar changes to serum PSA as dutasteride monotherapy. (notice Dutastéride, Mises en garde et précautions)

  • TérazosinealphabloquantMineure

    The effect of administration of tamsulosin or terazosin on dutasteride pharmacokinetic parameters has not been evaluated. (notice Dutastéride, Interactions médicamenteuses)

  • Ticagrélorantiagrégant plaquettaireMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

  • Voriconazoleantifongique azoléMineure

    The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. (notice Dutastéride, Interactions médicamenteuses)

Aucune interaction significative signalée (10)

  • AlfuzosinealphabloquantAucune interaction

    Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (notice Dutastéride, Interactions médicamenteuses)

  • CarvédilolbêtabloquantAucune interaction

    Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (notice Dutastéride, Interactions médicamenteuses)

  • Colestyraminechélateur des acides biliairesAucune interaction

    Cholestyramine Administration of a single 5-mg dose of dutasteride capsules followed 1 hour later by 12 g of cholestyramine does not affect the relative bioavailability of dutasteride [see Clinical Pharmacology (12.3) ]. (notice Dutastéride, Interactions médicamenteuses)

  • DoxazosinealphabloquantAucune interaction

    Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (notice Dutastéride, Interactions médicamenteuses)

  • LabétalolbêtabloquantAucune interaction

    Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (notice Dutastéride, Interactions médicamenteuses)

  • PhénoxybenzaminealphabloquantAucune interaction

    Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (notice Dutastéride, Interactions médicamenteuses)

  • PhentolaminealphabloquantAucune interaction

    Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (notice Dutastéride, Interactions médicamenteuses)

  • PrazosinealphabloquantAucune interaction

    Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (notice Dutastéride, Interactions médicamenteuses)

  • SilodosinealphabloquantAucune interaction

    Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (notice Dutastéride, Interactions médicamenteuses)

  • WarfarineanticoagulantAucune interaction

    Warfarin Concomitant administration of dutasteride capsules 0.5 mg/day for 3 weeks with warfarin does not alter the steady-state pharmacokinetics of the S- or R-warfarin isomers or alter the effect of warfarin on prothrombin time [see Clinical Pharmacology (12.3) ]. (notice Dutastéride, Interactions médicamenteuses)

Vérifiez Dutastéride avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.